Risk Stratification Using Dynamic International Prognostic Scoring System and Splenomegaly in Myelofibrosis Treated with Pretransplant JAK Inhibitors
- 4 September 2025
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (12) , 1008.e1-1008.e11
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)American Journal of Hematology, 2020
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With MyelofibrosisJAMA Oncology, 2018
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsTransplantation and Cellular Therapy, 2016
- Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantationInternational Journal of Hematology, 2015
- Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)International Journal of Hematology, 2015
- Outcome of Transplantation for MyelofibrosisTransplantation and Cellular Therapy, 2010
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2009
- Primary myelofibrosis: A detailed statistical analysis of the clinicopathological variables influencing survivalAnnals of Hematology, 1994
- Chronic graft-versus-host syndrome in manThe American Journal of Medicine, 1980